IMS 2026 – Exploring the risk of cardiovascular disease and associated symptoms in myeloma
Published:
How does cardiovascular risk change across the myeloma treatment pathway? Findings presented at IMS 2026 explored patterns in cardiovascular-related outcomes, including breathlessness, and what this could mean for monitoring in practice.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?